Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in ExperimentalCandida albicansInfection of the Central Nervous System
Citations Over TimeTop 10% of 2000 papers
Abstract
The central nervous system (CNS) distribution and antifungal efficacy of all 4 approved formulations of amphotericin B (AmB) were investigated in a rabbit model of hematogenous Candida albicans meningoencephalitis. Treatment with AmB deoxycholate (1 mg/kg/day) or liposomal AmB (5 mg/kg/day) yielded the highest peak plasma concentration (C(max)), area under concentration versus time curve from zero to 24 h (AUC(0-24)), and time during dosing level tau Ttau>minimum inhibitory complex (MIC) values and led to complete eradication of C. albicans from brain tissue (PMIC with clearance of C. albicans from brain tissue (P</=.0002). Although pharmacodynamic parameters derived from the MIC of free AmB were highly predictive of antifungal efficacy, parameters derived from MICs of individual formulations were not predictive. AmB deoxycholate and liposomal AmB had the greatest antifungal efficacy. This activity was concentration and time dependent.
Related Papers
- → Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations(2004)187 cited
- → What is the current and future status of conventional amphotericin B?(2006)148 cited
- → Lipid-based formulations of amphotericin B(2004)67 cited
- → Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment(2009)18 cited
- → Relapse of kala-azar after use of multiple drugs: A case report and brief review of literature(2012)10 cited